Trial Profile
A double blind, randomized, placebo-controlled, multiple ascending dose study to evaluate the pharmacokinetics, pharmacodynamics, immunogenecity and safety of Lulizumab Pegol in healthy volunteers (MAD study)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Oct 2016
Price :
$35
*
At a glance
- Drugs Lulizumab pegol (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 07 Oct 2016 New trial record